BIOS Fund III NT, LP 的 Form 4 申報
IN8BIO, Inc.（INAB），2025/5/7 申報
- 申報編號
- 0001104659-25-045738
- 申報時間
- 2025/5/7 21:47 ET
- 交易日
- 2025/5/2
- 申報延遲
- 5 天遲報
- 10b5-1 計畫
- 沒有勾選
這份申報列了 3 筆衍生性交易。交易後 5 天才申報，超過 2 個營業日的期限。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| BIOS Fund III NT, LPCIK 0001791910 | 持股 10% 以上大股東 |
| BIOS Fund III QP, LPCIK 0001791916 | 持股 10% 以上大股東 |
| BIOS Fund III, LPCIK 0001791917 | 持股 10% 以上大股東 |
| Cavu Management, LPCIK 0001813270 | 持股 10% 以上大股東 |
| Cavu Advisors, LLCCIK 0001813310 | 持股 10% 以上大股東 |
| BP Directors, LPCIK 0001813311 | 持股 10% 以上大股東 |
| Bios Equity Partners II, LPCIK 0001813313 | 持股 10% 以上大股東 |
| Bios Equity Partners, LPCIK 0001813314 | 持股 10% 以上大股東 |
| Kreis Leslie W.CIK 0001813316 | 持股 10% 以上大股東 |
| BIOS Equity Partners III, LPCIK 0001831976 | 持股 10% 以上大股東 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
這份申報沒有這一類的交易。
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
Pursuant to a Warrant Exchange Agreement (the "Warrant Exchange Agreement"), dated as of April 26, 2025, between In8bio, Inc. (the "Issuer") and Bios Clinical Opportunity Fund, LP ("Bios COF"), Bios COF purchased from the Issuer in a private placement 1,148,482 pre-funded warrants (the "Pre-Funded Warrants") to purchase one share of Common Stock in exchange for the surrender by Bios COF for cancellation of (i) 574,241 Series A Warrants to purchase one share of Common Stock, (ii) 574,241 Series B Warrants to purchase one share of Common Stock and (iii) payment to the Issuer of $204,774.34 in cash. The closing of the transactions contemplated by the Warrant Exchange Agreement occurred on May 2, 2025 . The Pre-Funded Warrants have an exercise price of $0.0001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full.
表 II 有 3 筆交易的價格引用這則附註。
備註
This Form 4 has been split into two filings because there are more than 10 reporting persons in total, and the SEC's EDGAR filing system limits a single Form 4 to a maximum of 10 reporting persons. The other Form 4 relating to the same event is being filed by Mr. Kreis as the designated filer. As the result of the transactions reported herein, together with other transactions by the Issuer, the reporting persons are no longer subject to Section 16 as of May 2, 2025.